Kartos Therapeutics Revenue and Competitors

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Kartos Therapeutics's estimated annual revenue is currently $17.2M per year.(i)
  • Kartos Therapeutics's estimated revenue per employee is $238,958

Employee Data

  • Kartos Therapeutics has 72 Employees.(i)
  • Kartos Therapeutics grew their employee count by -21% last year.

Kartos Therapeutics's People

NameTitleEmail/Phone
1
CEOReveal Email/Phone
2
Chief Scientific Officer at Kartos TherapeuticsReveal Email/Phone
3
SVP FinanceReveal Email/Phone
4
VP, Head Programming and Data OperationsReveal Email/Phone
5
SVP Clinical Development OperationsReveal Email/Phone
6
VP, Medical Affairs, The Americas and Asia-PacReveal Email/Phone
7
SVP - Strategy & Business DevelopmentReveal Email/Phone
8
VP, Medical WritingReveal Email/Phone
9
VP, Toxicology and Experimental MedicineReveal Email/Phone
10
VP, Translational ScienceReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$4.4M57-8%$53MN/A
#2
$21.2M137-26%$110MN/A
#3
$0.9M50%N/AN/A
#4
$2.3M1515%N/AN/A
#5
$1.6M4-50%N/AN/A
#6
$0.7M80%N/AN/A
#7
$11.5M74-12%N/AN/A
#8
$0.4M27510%$236.7MN/A
#9
$4M51-74%$160MN/A
#10
$2.3M1731%N/AN/A
Add Company

What Is Kartos Therapeutics?

Kartos Therapeutics is a privately held, clinical-stage biopharmaceutical company developing a potentially best-in-class MDM2 inhibitor. Launched in 2018 by proven industry veterans, we are a passionate team based in Redwood City, California, and Bellevue, Washington. We have brought together scientists and clinicians with a deep understanding of hematology and oncology and an experienced leadership team. Together, we’re building an exciting biotechnology company with a culture defined by caring, ambition, dedication, and teamwork!

keywords:N/A

N/A

Total Funding

72

Number of Employees

$17.2M

Revenue (est)

-21%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$9.1M72-17%$20M
#2
$12.8M727%$29.3M
#3
$9.1M72-16%N/A
#4
$3.5M7410%N/A
#5
$9.3M74N/AN/A